“Drugs in the COVID-19 pandemic: Analysis of the commercialization of azithromycin, hydroxychloroquine, ivermectin and nitazoxanide in Brazil” (2022) Research, Society and Development, 11(6), p. e16711628726. doi:10.33448/rsd-v11i6.28726.